Xiamen Amoytop Biotech News

Tebao Biotech (688278): Leading provider of hepatitis B interferon treatment, deepens development of recombinant protein drugs

Jun 26 00:00

Tebao Biotech (688278): The marketing application for continued rapid dosage of Pegbin for clinical treatment of slow hepatitis B was accepted

Apr 23 14:56

Guojin Securities released a research report on April 23 stating that it gave Tebao Biotech (688278.SH) a purchase rating. The main reasons for the rating include: 1) clinical evidence of hepatitis B cure continues to accumulate, and Pegobin continues to

Zhitong FinanceApr 23 10:56

Tebao Biotech (688278): The core product Pegbin rapidly releases the company's performance and continues to grow

Apr 23 09:56

Tebao Biotech (688278): Sales of the core product Pegbin increased 54% year-on-year, and the application for clinical treatment of slow hepatitis B was accepted

Apr 17 14:51

Haitong International released a research report on April 15 stating that it gave Tebao Biotech (688278.SH) an superior rating to the market, and the target price was 89.20 yuan. The main reasons for the rating include: 1) continued revenue growth driven

Zhitong FinanceApr 16 07:21

Tebao Biotech (688278): Continued release of Teboson Pegbin drives high performance growth, and new products enter the harvest period

Apr 14 00:00

Tebao Biotech (688278): Continued release of Pegbin drives high performance growth, and new products enter the harvest period

Apr 11 19:26

Tepao Biotech (688278) 2023 Annual Report Review Report: The company's 2023 performance grew rapidly and innovative products continued to be implemented

Apr 4 00:00

Tebao Biotech (688278): 23FY revenue is growing rapidly, and academic programs have accumulated strength

Mar 31 00:00

Tebao Biotech (688278): Sustained release of long-acting interferon, long-acting brightening drug, and long-term growth hormone are gradually entering the commercial implementation stage

Mar 31 00:00

Tebao Biotech (688278): The core product Pegbin High Speed Release Company's performance is growing rapidly

Mar 29 10:46

Tebao Biotech (688278): The rapid growth in Pegbin's sales revenue is progressing steadily in the research pipeline

Mar 29 00:00

Tebao Biotech (688278) Company Comment: Increased Indications, Marketing Applications Accepted, Slow B Treatment Further Deepened

Mar 16 00:00

Tebao Biotech (688278): Broad hepatitis B market space, rapid release of polyethylene glycol interferon-α

Mar 10 00:00

Tebao Biotech (688278) Company Review: Hepatitis B Clinical Cure Continues to Be In-depth, Performance Forecast Exceeds Expectations

Jan 15 00:00

Tebao Biotech (688278): Yipei's application for marketing of growth hormone has been accepted, and the product line is expected to be further enriched

Jan 11 07:56

Tebao Biotech (688278): Jiangxi Interferon Interferon Provincial Alliance, the decline in collection and implementation is moderate, which is conducive to long-term price stability

Dec 17, 2023 00:00

Tebao Biotech (688278): Continued dosage of Pegerbin can be expected to contribute to the performance of long-term whitening drugs

Oct 22, 2023 00:00

Tebao Biotech (688278): High quarterly profit growth, new products are expected to bring in new volume

Oct 20, 2023 20:02